In concordance, they also demonstrated that inhibition of SRC-3 activity suppresses IL-17A expression in γδ T cells, reduces the multiple myeloma progression in mouse models and enhances the efficacy of bortezomib [151]. Here, NCOA3 is linked to plasma cell myeloma.